NDA 211996 · Foldrx Pharms
Vyndaqel
Tafamidis Meglumine · Oral
NovelBreakthrough therapyPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
May 3, 2019
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
37
7 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Tafamidis Meglumine" as an intervention, any sponsor and status, largest first.
- Long-term Safety of Tafamidis in Subjects With Transthyretin CardiomyopathyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02791230 · 1,733 participants · Start Jun 13, 2016 · Primary completion Oct 26, 2023
Drug: Tafamidis · For: Transthyretin (TTR) Amyloid Cardiomyopathy
Sites: Birmingham, Alabama; Beverly Hills, California; La Jolla, California · 80 sites in all
- Safety and Efficacy of Tafamidis in Patients With Transthyretin CardiomyopathyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01994889 · 441 participants · Start Dec 9, 2013 · Primary completion Feb 7, 2018
Drug: Tafamidis; Tafamidis and 1 more · For: Transthyretin (TTR) Amyloid Cardiomyopathy
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 80 sites in all
- Safety and Efficacy Study of Fx-1006A in Patients With Familial AmyloidosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00409175 · 128 participants · Start Jan 2007 · Primary completion May 2009
Drug: Fx-1006A; Placebo · For: Familial Amyloid Polyneuropathy
Sites: Boston, Massachusetts; Ciudad de Buenos Aires, Argentina; Rio de Janeiro, Brazil · 10 sites in all
- Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin AmyloidosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00925002 · 93 participants · Start Aug 5, 2009 · Primary completion Jul 8, 2020
Drug: Tafamidis · For: ATTR-PN
Sites: Baltimore, Maryland; Buenos Aires, Argentina; Rio de Jameiro, Brazil · 9 sites in all
- An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid PolyneuropathyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00791492 · 86 participants · Start Jul 2008 · Primary completion Aug 2008
Drug: Fx-1006A · For: Familial Amyloid Polyneuropathy; ATTR-PN
Sites: Buenos Aires, Argentina; Ciudad de Buenos Aires, Argentina; Rio de Janeiro, Brazil · 11 sites in all
PfizerPfizer (PFE)
NCT04814186 · 53 participants · Start Jul 22, 2021 · Primary completion Oct 16, 2023
Drug: Tafamidis · For: Transthyretin Amyloid Cardiomyopathy
Sites: Beijing, China; Wuhan, China; Changsha, China · 9 sites in all
BayerBayer (BAYRY)
NCT07298044 · 50 participants (planned) · Start Feb 13, 2026 · Primary completion Sep 17, 2027
Drug: Acoramidis · For: Transthyretin Amyloid Cardiomyopathy
Sites: Sankt Pölten, Austria; Vienna, Austria; Braunau am Inn, Austria · 26 sites in all
PfizerPfizer (PFE)
NCT01775761 · 42 participants · Start Jan 2013 · Primary completion Apr 2013
Drug: Period 1; Period 2 and 1 more · For: TTR Cardiomyopathy
Sites: New Haven, Connecticut; Brussels, Belgium; Singapore, Singapore
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vyndaqel (Tafamidis Meglumine)
2024 spending
$304M
Beneficiaries
2,021
12,673 claims
Per beneficiary
$150,211
$181.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $199,634,904 |
| 2021 | $126,772,500 |
| 2022 | $109,330,317 |
| 2023 | $118,169,381 |
| 2024 | $303,575,850 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Shah SJ, Fine N, Garcia-Pavia P, et al. · JAMA Cardiol 2024 · Randomized Controlled Trial, Multicenter Study
- Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.
Grogan M, Davis MK, Crespo-Leiro MG, et al. · Eur J Heart Fail 2024 · Randomized Controlled Trial, Multicenter Study
- The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers.
Lockwood PA, Le VH, O'Gorman MT, et al. · Clin Pharmacol Drug Dev 2020 · Clinical Trial, Phase I, Comparative Study
- Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.
Merlini G, Planté-Bordeneuve V, Judge DP, et al. · J Cardiovasc Transl Res 2013 · Clinical Trial, Phase II, Multicenter Study
- Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Sperry BW, Hanna M, Maurer MS, et al. · JAMA Cardiol 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
Waddington Cruz M, Amass L, Keohane D, et al. · Amyloid 2016 · Randomized Controlled Trial
Sponsor: Foldrx Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.